Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Strategy & Legal Officer | August 01, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,968 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Tax withholding · Disposed 4,699 · Balance 205,968 F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2026 Filed Aug 4, 2026 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,699 | $9.69 | $45,533.31 |
DisclosureSEC source: 0001521123-26-000008 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,968 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:47 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,700 | $11.16 | $52,452.00 |
DisclosureSEC source: 0001521123-26-000006 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,667 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 39,650 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001521123-26-000004 · primarydocument.xml · derivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,650 Underlying: Common Stock · 39,650 shares Expires 2036-01-06 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 73,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001521123-26-000004 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,367 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 9,793 | $14.40 | $141,019.20 |
DisclosureSEC source: 0001521123-26-000002 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,618 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,699 | $8.19 | $38,484.81 |
DisclosureSEC source: 0001562180-25-005618 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Strategy & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,411 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2025. Read SEC document |
| February 01, 2025 Filed Apr 4, 2025 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,700 | $8.07 | $37,929.00 |
DisclosureSEC source: 0001562180-25-003010 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,110 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 223,350 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001562180-25-000186 · primarydocument.xml · derivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,350 Underlying: Common Stock · 223,350 shares Expires 2035-01-02 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 11,395 | $7.73 | $88,083.35 |
DisclosureSEC source: 0001562180-25-000186 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,810 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 56,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006016 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,205 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of February 1, 2025, August 1, 2025, February 1, 2026 and August 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 54,945 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001562180-24-000219 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,945 Underlying: Common Stock · 54,945 shares Expires 2034-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 34,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000219 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,759 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 7,893 | $17.95 | $141,679.35 |
DisclosureSEC source: 0001562180-24-000219 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,144 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 56,519 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-23-000219 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,519 Underlying: Common Stock · 56,519 shares Expires 2033-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 67,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000219 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,037 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,843 | $22.68 | $41,799.24 |
DisclosureSEC source: 0001562180-23-000219 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,097 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 37,400 | $0.00 Strike: $34.31 | $0.00 |
DisclosureSEC source: 0001562180-22-000155 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,400 Underlying: Common Stock · 37,400 shares Expires 2032-01-03 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000155 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,940 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,332 | $32.70 | $43,556.40 |
DisclosureSEC source: 0001562180-22-000155 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,040 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,701 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-21-001215 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,430 Underlying: Common Stock · 4,701 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,701 | $49.08 | $230,725.08 |
DisclosureSEC source: 0001562180-21-001215 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.00 to $49.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,701 | $12.10 | $56,882.10 |
DisclosureSEC source: 0001562180-21-001215 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,300 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-21-001045 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,131 Underlying: Common Stock · 1,300 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,300 | $49.11 | $63,843.00 |
DisclosureSEC source: 0001562180-21-001045 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.00 to $49.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,300 | $12.10 | $15,730.00 |
DisclosureSEC source: 0001562180-21-001045 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-21-000913 · primarydocument.xml · derivative · entry 4 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,431 Underlying: Common Stock · 10,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 500 | $45.13 | $22,565.00 |
DisclosureSEC source: 0001562180-21-000913 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.13 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,500 | $44.77 | $425,315.00 |
DisclosureSEC source: 0001562180-21-000913 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,872 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.095 to $45.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $12.10 | $121,000.00 |
DisclosureSEC source: 0001562180-21-000913 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,378 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · derivative · entry 13 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641 Underlying: Common Stock · 1,378 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 11,100 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,378 | $49.15 | $67,728.70 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 9 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $49.00 to $49.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,378 | $19.50 | $26,871.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 8 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,622 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · derivative · entry 12 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,019 Underlying: Common Stock · 2,622 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 11,100 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · derivative · entry 11 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,431 Underlying: Common Stock · 7,500 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,122 | $49.08 | $496,787.76 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 7 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.00 to $49.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,622 | $19.50 | $51,129.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 6 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 7,500 | $12.10 | $90,750.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 5 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · derivative · entry 10 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,931 Underlying: Common Stock · 10,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,320 | $48.13 | $63,531.60 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.87 to $48.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,062 | $47.42 | $192,620.04 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,692 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.87 to $47.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,618 | $46.43 | $214,413.74 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,754 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.86 to $46.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:48 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $12.10 | $121,000.00 |
DisclosureSEC source: 0001562180-21-000307 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:52 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $44.97 | $0.00 |
DisclosureSEC source: 0001562180-21-000140 · primarydocument.xml · derivative · entry 2 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2031-01-04 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:52 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 13,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000140 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001562180-20-000220 · primarydocument.xml · derivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-19-004820 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,931 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,486 | $42.00 | $230,412.00 |
DisclosureSEC source: 0001562180-19-004820 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,572 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-19-004820 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 19, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · derivative · entry 7 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,641 Underlying: Common Stock · 4,900 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 11,100 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| July 19, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,900 | $50.03 | $245,147.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · nonDerivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.